181 related articles for article (PubMed ID: 16180125)
1. Pharmacokinetic differences between pantoprazole enantiomers in rats.
Xie Z; Zhang Y; Xu H; Zhong D
Pharm Res; 2005 Oct; 22(10):1678-84. PubMed ID: 16180125
[TBL] [Abstract][Full Text] [Related]
2. Stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor, in extensive and poor metabolizers of S-mephenytoin.
Tanaka M; Ohkubo T; Otani K; Suzuki A; Kaneko S; Sugawara K; Ryokawa Y; Ishizaki T
Clin Pharmacol Ther; 2001 Mar; 69(3):108-13. PubMed ID: 11240974
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
Andersson T
Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic differences between lansoprazole enantiomers and contribution of cytochrome P450 isoforms to enantioselective metabolism of lansoprazole in dogs.
Masa K; Hamada A; Arimori K; Fujii J; Nakano M
Biol Pharm Bull; 2001 Mar; 24(3):274-7. PubMed ID: 11256484
[TBL] [Abstract][Full Text] [Related]
5. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype.
Tanaka M; Ohkubo T; Otani K; Suzuki A; Kaneko S; Sugawara K; Ryokawa Y; Hakusui H; Yamamori S; Ishizaki T
Clin Pharmacol Ther; 1997 Dec; 62(6):619-28. PubMed ID: 9433390
[TBL] [Abstract][Full Text] [Related]
6. The H+, K(+)-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole.
Simon WA; Büdingen C; Fahr S; Kinder B; Koske M
Biochem Pharmacol; 1991 Jul; 42(2):347-55. PubMed ID: 1650212
[TBL] [Abstract][Full Text] [Related]
7. Stereoselective chiral inversion of pantoprazole enantiomers after separate doses to rats.
Masubuchi N; Yamazaki H; Tanaka M
Chirality; 1998; 10(8):747-53. PubMed ID: 9803530
[TBL] [Abstract][Full Text] [Related]
8. Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.
Kim KA; Shon JH; Park JY; Yoon YR; Kim MJ; Yun DH; Kim MK; Cha IJ; Hyun MH; Shin JG
Clin Pharmacol Ther; 2002 Jul; 72(1):90-9. PubMed ID: 12152007
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.
Andersson T; Holmberg J; Röhss K; Walan A
Br J Clin Pharmacol; 1998 Apr; 45(4):369-75. PubMed ID: 9578184
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of pantoprazole in man.
Huber R; Hartmann M; Bliesath H; Lühmann R; Steinijans VW; Zech K
Int J Clin Pharmacol Ther; 1996 May; 34(5):185-94. PubMed ID: 8738854
[TBL] [Abstract][Full Text] [Related]
11. Similarities and differences in the properties of substituted benzimidazoles: a comparison between pantoprazole and related compounds.
Kromer W
Digestion; 1995; 56(6):443-54. PubMed ID: 8536813
[TBL] [Abstract][Full Text] [Related]
12. Stereoselective metabolism of lansoprazole by human liver cytochrome P450 enzymes.
Kim KA; Kim MJ; Park JY; Shon JH; Yoon YR; Lee SS; Liu KH; Chun JH; Hyun MH; Shin JG
Drug Metab Dispos; 2003 Oct; 31(10):1227-34. PubMed ID: 12975331
[TBL] [Abstract][Full Text] [Related]
13. Effects of pantoprazole on xenobiotic metabolizing enzymes in rat liver microsomes: a comparison with other proton pump inhibitors.
Masubuchi N; Hakusui H; Okazaki O
Drug Metab Dispos; 1997 May; 25(5):584-9. PubMed ID: 9152597
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers.
Calabresi L; Pazzucconi F; Ferrara S; Di Paolo A; Tacca MD; Sirtori C
Pharmacol Res; 2004 May; 49(5):493-9. PubMed ID: 14998561
[TBL] [Abstract][Full Text] [Related]
15. Lack of pantoprazole drug interactions in man.
Steinijans VW; Huber R; Hartmann M; Zech K; Bliesath H; Wurst W; Radtke HW
Int J Clin Pharmacol Ther; 1994 Aug; 32(8):385-99. PubMed ID: 7981922
[TBL] [Abstract][Full Text] [Related]
16. Pantoprazole has no influence on steady state pharmacokinetics and pharmacodynamics of metoprolol in healthy volunteers.
Koch HJ; Hartmann M; Bliesath H; Huber R; Steinijans VW; Mascher H; Wurst W
Int J Clin Pharmacol Ther; 1996 Oct; 34(10):420-3. PubMed ID: 8897078
[TBL] [Abstract][Full Text] [Related]
17. Differences in binding properties of two proton pump inhibitors on the gastric H+,K+-ATPase in vivo.
Shin JM; Sachs G
Biochem Pharmacol; 2004 Dec; 68(11):2117-27. PubMed ID: 15498502
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic differences between lansoprazole enantiomers in rats.
Arimori K; Yasuda K; Katsuki H; Nakano M
J Pharm Pharmacol; 1998 Nov; 50(11):1241-5. PubMed ID: 9877309
[TBL] [Abstract][Full Text] [Related]
19. Pantoprazole does not interact with nifedipine in man under steady-state conditions.
Bliesath H; Huber R; Steinijans VW; Koch HJ; Kunz K; Wurst W
Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S81-5. PubMed ID: 8793608
[TBL] [Abstract][Full Text] [Related]
20. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes.
Abelö A; Andersson TB; Antonsson M; Naudot AK; Skånberg I; Weidolf L
Drug Metab Dispos; 2000 Aug; 28(8):966-72. PubMed ID: 10901708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
